SCHEMBL16790891

SCHEMBL16790891

COC(=O)CN(C)CCN(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
TSHR P16473 4/20 0.40
GAA P10253 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8378681 0.83 KMT2A (0.54) MEN1KMT2ACA12CA14TSHR
SCHEMBL1811802 0.82 KMT2A (0.50) MEN1KMT2ACA12CA14TSHR
SCHEMBL1692353 0.82 KMT2A (0.50) MEN1KMT2ACA12CA14TSHR
SCHEMBL6405180 0.82 MEN1 (0.50) MEN1KMT2ACA12CA2CA9
SCHEMBL15623091 0.80 MEN1 (0.48) MEN1KMT2ATSHRGAAHSD17B10
SCHEMBL30418438 0.80 MEN1 (0.48) MEN1KMT2ATSHRGAAHSD17B10
SCHEMBL21159200 0.79 MEN1 (0.44) MEN1KMT2ACA12CA2CA9
SCHEMBL196772 0.78
SCHEMBL21775914 0.77 MEN1 (0.45) MEN1KMT2ACA12CA14TSHR
SCHEMBL20674802 0.77 CA12 (0.39) MEN1KMT2ACA12CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023250375-A1 CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA ORNA THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed
EP-4289951-A2 CIRCULAR RNA COMPOSITIONS AND METHODS Orna Therapeutics, Inc. (US) 2023-12-13 EP disclosed
WO-2023056033-A1 LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES ORNA THERAPEUTICS, INC. (US) 2023-04-06 WO disclosed
WO-2022261490-A2 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. (US) 2022-12-15 WO disclosed
WO-2021226597-A2 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed
WO-2021189059-A2 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021113777-A2 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. (US) 2021-06-10 WO disclosed
WO-2021030701-A1 IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS Acuitas Therapeutics, Inc. (CA) 2021-02-18 WO disclosed
US-9999852-B2 Method for removing SOx from gas with compound alcohol-amine solution BEIJING BOYUAN HENGSHENG HIGH-TECHNOLOGY CO., LTD (CN) 2018-06-19 US disclosed
WO-2018081480-A1 LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2018-05-03 WO disclosed
WO-2017117528-A1 LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS Acuitas Therapeutics, Inc. (CA) 2017-07-06 WO disclosed
US-20150160555-A1 PATTERN FORMING METHOD, AND, METHOD FOR PRODUCING ELECTRONIC DEVICE AND ELECTRONIC DEVICE, EACH USING THE SAME FUJIFILM CORPORATION (JP) 2015-06-11 US disclosed